AEMD Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -- compared to Aethlon Medical, Inc.'s net margin of -13.47%. Aethlon Medical, Inc.'s return on equity of -227.35% beat Accuray, Inc.'s return on equity of -60.6%.

Aethlon Medical, Inc. has a consensus price target of $4.75, signalling upside risk potential of 127.27%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 372.4%. Given that Accuray, Inc. has higher upside potential than Aethlon Medical, Inc., analysts believe Accuray, Inc. is more attractive than Aethlon Medical, Inc..

Aethlon Medical, Inc. has a beta of 1.597, which suggesting that the stock is 59.684% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

Aethlon Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Aethlon Medical, Inc. quarterly revenues are --, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Aethlon Medical, Inc.'s net income of -$2M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Aethlon Medical, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical, Inc. is -- versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -- compared to Aethlon Medical, Inc.'s net margin of -14.54%. Aethlon Medical, Inc.'s return on equity of -227.35% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

Aethlon Medical, Inc. has a consensus price target of $4.75, signalling upside risk potential of 127.27%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 81.8%. Given that Aethlon Medical, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Aethlon Medical, Inc. is more attractive than Alphatec Holdings, Inc..

Aethlon Medical, Inc. has a beta of 1.597, which suggesting that the stock is 59.684% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

Aethlon Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Aethlon Medical, Inc. quarterly revenues are --, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. Aethlon Medical, Inc.'s net income of -$2M is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, Aethlon Medical, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical, Inc. is -- versus 2.76x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -- compared to Aethlon Medical, Inc.'s net margin of 12.68%. Aethlon Medical, Inc.'s return on equity of -227.35% beat Boston Scientific Corp.'s return on equity of 12.55%.

Aethlon Medical, Inc. has a consensus price target of $4.75, signalling upside risk potential of 127.27%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.78 which suggests that it could grow by 37.36%. Given that Aethlon Medical, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Aethlon Medical, Inc. is more attractive than Boston Scientific Corp..

Aethlon Medical, Inc. has a beta of 1.597, which suggesting that the stock is 59.684% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Aethlon Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Aethlon Medical, Inc. quarterly revenues are --, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Aethlon Medical, Inc.'s net income of -$2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Aethlon Medical, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical, Inc. is -- versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Aethlon Medical, Inc.'s net margin of -316.61%. Aethlon Medical, Inc.'s return on equity of -227.35% beat Plus Therapeutics, Inc.'s return on equity of --.

Aethlon Medical, Inc. has a consensus price target of $4.75, signalling upside risk potential of 127.27%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1843.46%. Given that Plus Therapeutics, Inc. has higher upside potential than Aethlon Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Aethlon Medical, Inc..

Aethlon Medical, Inc. has a beta of 1.597, which suggesting that the stock is 59.684% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Aethlon Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aethlon Medical, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Aethlon Medical, Inc.'s net income of -$2M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Aethlon Medical, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical, Inc. is -- versus 4.54x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.